Peter Lipscomb, MD
Ophthalmology · Hickory, NCNPI 1437598273
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations.
Across 108 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$400
- Thea Pharma Inc.$383
- Alcon$353
- AbbVie$173
- Johnson & Johnson Surgical Vision, Inc.$161
- Kala Pharmaceuticals, Inc.$78
- plus $508 from 16 others
Across 33 payments — averaging $40.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Notal Vision, Inc.$1K
What the payments were for
- Food & beverage$2,055100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 27 | $400 |
| Thea Pharma Inc. | 24 | $383 |
| Alcon | 15 | $353 |
| AbbVie(2 entities) | 11 | $173 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $161 |
| Kala Pharmaceuticals, Inc. | 5 | $78 |
| Oyster Point Pharma, Inc. | 3 | $70 |
| Lensar, Inc. | 1 | $52 |
| Notal Vision, Inc. | 3 | $50 |
| Rayner Intraocular Lenses Limited | 2 | $47 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $41 |
| Aerie Pharmaceuticals, Inc. | 2 | $39 |
| Novartis | 1 | $38 |
| Tarsus Pharmaceuticals, Inc. | 1 | $26 |
| Bausch & Lomb Americas Inc. | 1 | $24 |
| Sight Sciences, Inc. | 1 | $22 |
| Biotissue Holdings Inc. | 1 | $21 |
| Carl Zeiss Meditec USA, Inc. | 1 | $19 |
| Rxsight Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Omeros Corporation | 1 | $12 |
| Eyepoint US, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$124
How this compares
$2,055 in reported general payments places this provider in the 55th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 84 | $103,943 |
| TyrvayaVarenicline Tartrate | 22 | $19,289 |
| LumiganBimatoprost | 48 | $16,928 |
| RocklatanNetarsudil Mesylat/Latanoprost | 24 | $8,727 |
| CombiganBrimonidine Tartrate/Timolol | 27 | $7,281 |
| Latanoprost | 730 | $6,195 |
| Prednisolone Acetate | 153 | $5,741 |
| RhopressaNetarsudil Mesylate | 15 | $5,205 |
| Brimonidine Tartrate | 127 | $4,552 |
| TafluprostTafluprost/Pf | 32 | $4,354 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 220 | $2,595 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 16 | $2,415 |
| Timolol Maleate | 220 | $2,240 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 109 | $1,653 |
| ValacyclovirValacyclovir Hcl | 33 | $1,495 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $173 | $128,152159 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $70 | $19,28922 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $39 | $13,93239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 ophthalmology providers in North Carolina.
Other ophthalmology in Hickory
- Preeya GuptaRaleigh$1.8M
- Julie WoodwardDurham$1M
- Rajiv ShahWinston Salem$909K
- Lejla VajzovicDurham$681K
- Karl StonecipherGreensboro$653K
- Terry KimDurham$605K
- Keith WalterWinston Salem$397K
- Leon HerndonDurham$230K
- Thomas MundorfCharlotte$220K
- Glenn JaffeDurham$218K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.